LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 93

Search options

  1. Article ; Online: Fertility-sparing approach to malignant ovarian germ cell tumors - Oncologic and obstetric outocome: A retrospective study.

    Ayhan, Ali / Tunç, Mehmet / Akıllı, Hüseyin / Haberal, Nihan / Haberal, Ali

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

    2023  Volume 164, Issue 3, Page(s) 1074–1079

    Abstract: Objective: To evaluate oncologic (such as disease-free and overall survival) and obstetric outcomes in patients diagnosed with malignant ovarian germ cell tumors (MOGCTs).: Methods: Patients diagnosed with MOGCTs between March 2007 and February 2022 ... ...

    Abstract Objective: To evaluate oncologic (such as disease-free and overall survival) and obstetric outcomes in patients diagnosed with malignant ovarian germ cell tumors (MOGCTs).
    Methods: Patients diagnosed with MOGCTs between March 2007 and February 2022 were evaluated and patients who underwent fertility sparing surgery were included in this retrospective study. The obstetric and oncologic outcomes were evaluated by collecting data up until the patient's last follow-up visit from the hospital records and patient files. The study was approved by Başkent University Institutional Review Board (KA23/124).
    Results: Seventy FSS patients were included in this study. The median age of the patients was 22.5 years (range: 11-37). The median follow-up time was 92.0 months (10-189). Immature teratoma was the most common histological subtype (32.9%). Bilateral involvement was detected in only one patient with immature teratoma (1.4%). The 5-year DFS rates of immature teratoma, dysgerminoma, yolk sac, and mixed germ cell histologic types were 91.1%, 94.1%, 82.4%, and 88.9%, respectively (P: 0.716). The 5-year OS rates of the same histologic types were 95.7%, 100%, 88.2%, and 88.9%, respectively (P = 0.487). All patients (100%) had a regular menstrual cycle after the completion of adjuvant treatment. The mean time between the last chemotherapy and menstruation was 4.38 months. To date, a total of 34 patients tried to conceive after the completion of disease treatment. A total of 23 (67.6%) patients conceived, resulting in 27 live births in 22 (100%) patients.
    Conclusion: Fertility preservation should be the first treatment option in MOGCTs in young patients due to the unilateral involvement of the disease and its chemosensitive nature.
    MeSH term(s) Pregnancy ; Female ; Humans ; Child ; Adolescent ; Young Adult ; Adult ; Retrospective Studies ; Neoplasms, Germ Cell and Embryonal/surgery ; Neoplasms, Germ Cell and Embryonal/pathology ; Ovarian Neoplasms/surgery ; Ovarian Neoplasms/drug therapy ; Teratoma/surgery ; Fertility Preservation/methods ; Neoplasm Staging
    Language English
    Publishing date 2023-09-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80149-5
    ISSN 1879-3479 ; 0020-7292
    ISSN (online) 1879-3479
    ISSN 0020-7292
    DOI 10.1002/ijgo.15141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.

    Ayhan, Ali / Akilli, Huseyin

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

    2020  Volume 152, Issue 2, Page(s) 202–207

    Abstract: Objective: To identify factors affecting survival for women undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).: Methods: A retrospective study at Baskent University School of Medicine, Ankara, Turkey. Data were ... ...

    Abstract Objective: To identify factors affecting survival for women undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
    Methods: A retrospective study at Baskent University School of Medicine, Ankara, Turkey. Data were evaluated for 71 women with recurrent ovarian cancer who underwent cytoreductive surgery with R0 resection plus HIPEC between 2016 and 2019. Potential factors affecting survival (platinum sensitivity, bevacizumab administration before HIPEC, albumin and CA125 levels, presence of ascites, age, number of chemotherapy lines, and time interval between last chemotherapy and HIPEC) were evaluated. Complications of HIPEC were documented.
    Results: The median age was 58 years, and the median follow-up was 12 months. In univariate analyses, platinum sensitivity, albumin level, and time since last chemotherapy cycle affected overall survival. In multivariate Cox regression analysis, use of bevacizumab before HIPEC (hazard ratio [HR], 6.7; 95% confidence interval [CI], 1.39-32.3; P=0.018) and presence of ascites (HR, 5.3; 95% CI, 1.65-17.5; P=0.005) were independent negative prognostic factors. Seven (8.9%) women experienced grade III-IV complications.
    Conclusion: In recurrent ovarian cancer, HIPEC is a promising treatment with mild-to-moderate toxicity. However, the presence of ascites and progression under bevacizumab treatment before HIPEC seem to be negative prognostic factors; these findings will be important for patient selection.
    MeSH term(s) Adult ; Aged ; Cytoreduction Surgical Procedures ; Female ; Humans ; Hyperthermic Intraperitoneal Chemotherapy ; Middle Aged ; Ovarian Neoplasms/surgery ; Ovarian Neoplasms/therapy ; Prognosis ; Retrospective Studies ; Turkey ; Young Adult
    Language English
    Publishing date 2020-10-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80149-5
    ISSN 1879-3479 ; 0020-7292
    ISSN (online) 1879-3479
    ISSN 0020-7292
    DOI 10.1002/ijgo.13410
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?

    Ayhan, Ali / Akilli, Huseyin / Abasiyanik, Mehmet Ali / Taskiran, Cagatay

    Journal of surgical oncology

    2022  Volume 127, Issue 3, Page(s) 457–464

    Abstract: Objective: The aim of this study is to evaluate the progression-free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).: Materials and methods: ROC ... ...

    Abstract Objective: The aim of this study is to evaluate the progression-free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
    Materials and methods: ROC patients who underwent cytoreductive surgery plus HIPEC between 2015 and 2021 were retrospectively evaluated. Patients' demographic information and clinicopathological characteristics including cancer type, histology, platinum status, presence of ascites, type of surgery, complications, chemotherapy history, and disease progression were documented. PFS was calculated using the Kaplan-Meier method.
    Results: A total of 104 patients with ROC were included. The median age was 57 years and the median follow-up time was 15 months (range: 5-69 months). In Cox regression multivariate analyses, platinum resistance (hazard ratio [HR]: 3.32, 95% confidence interval [CI]: 1.91-5.76, p = 0.00), more than one relapse prior HIPEC (HR: 2.81, 95% CI: 1.65-4.87, p = 0.024), and presence of ascites (HR: 1.88, 95% CI: 1.08-3.26, p = 0.00) were found to be negative prognostic factors for PFS. In subgroup analyses of patients with the first recurrence, the median PFS was 21 months for platinum-sensitive patients and 6 months for platinum-resistant patients (p = 0.032).
    Conclusion: HIPEC at the time of first platinum-sensitive relapse may lead to favorable PFS in the treatment ROC. However, HIPEC as salvage treatment even with R0 cytoreductive surgery does not seem effective.
    MeSH term(s) Humans ; Female ; Middle Aged ; Hyperthermic Intraperitoneal Chemotherapy ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Retrospective Studies ; Ascites/etiology ; Ascites/therapy ; Hyperthermia, Induced/methods ; Carcinoma, Ovarian Epithelial/therapy ; Combined Modality Therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Recurrence ; Cytoreduction Surgical Procedures/methods
    Language English
    Publishing date 2022-10-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82063-5
    ISSN 1096-9098 ; 0022-4790
    ISSN (online) 1096-9098
    ISSN 0022-4790
    DOI 10.1002/jso.27125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.

    Akilli, Huseyin / Rahatli, Samed / Aliyeva, Khayala / Altundag, Ozden / Kuscu, Ulku Esra / Ayhan, Ali

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

    2022  Volume 42, Issue 6, Page(s) 2230–2234

    Abstract: A retrospective observational study was carried out in Baskent University School of Medicine, Ankara, Turkey. Recurrent ovarian cancer patients treated between 2007 and 2017 were divided into two groups according to their bevacizumab status. The primary ... ...

    Abstract A retrospective observational study was carried out in Baskent University School of Medicine, Ankara, Turkey. Recurrent ovarian cancer patients treated between 2007 and 2017 were divided into two groups according to their bevacizumab status. The primary endpoints were overall survival (OS) and safety. Three hundred and ninety-six patients enrolled in this study, 200 (50.5%) received bevacizumab while 196 (49.5%) patients never received bevacizumab. The median follow-up time was 48.2 and 47.6 months, respectively. The 5-year OS was 61% and 46%, respectively (
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/adverse effects ; Carcinoma, Ovarian Epithelial/drug therapy ; Disease-Free Survival ; Female ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/drug therapy ; Platinum/therapeutic use
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Platinum (49DFR088MY)
    Language English
    Publishing date 2022-03-09
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 604639-3
    ISSN 1364-6893 ; 0144-3615
    ISSN (online) 1364-6893
    ISSN 0144-3615
    DOI 10.1080/01443615.2022.2036967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Frontline fighters: the continued fight against COVID-19.

    Akilli, Huseyin / Celik, Husnu / Taskiran, Cagatay / Bilir, Esra / Gultekin, Murat

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2020  Volume 30, Issue 7, Page(s) 1077–1078

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/prevention & control ; Gynecology/history ; History, 20th Century ; History, 21st Century ; Humans ; Medical Oncology/history ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; SARS-CoV-2 ; Turkey
    Keywords covid19
    Language English
    Publishing date 2020-05-23
    Publishing country England
    Document type Biography ; Historical Article ; Journal Article ; Portrait
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2020-001534
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prognostic value of the number of the metastatic lymph nodes in locally early-stage cervical cancer: squamous cell carcinoma versus non-squamous cell carcinoma.

    Aslan, Koray / Haberal, Ali / Akıllı, Hüseyin / Meydanli, Mehmet Mutlu / Ayhan, Ali

    Archives of gynecology and obstetrics

    2021  Volume 304, Issue 5, Page(s) 1279–1289

    Abstract: Purpose: To clarify the prognostic value of the number of metastatic lymph nodes (mLNs) in squamous and non-squamous histologies among women with node-positive cervical cancer.: Methods: One hundred ninety-one node-positive cervical cancer patients ... ...

    Abstract Purpose: To clarify the prognostic value of the number of metastatic lymph nodes (mLNs) in squamous and non-squamous histologies among women with node-positive cervical cancer.
    Methods: One hundred ninety-one node-positive cervical cancer patients who had undergone radical hysterectomy plus systematic pelvic and para-aortic lymphadenectomy followed by concurrent radiochemotherapy were retrospectively reviewed. The prognostic value of the number of mLNs was investigated in squamous cell carcinoma (SCC) v (n = 148) and non-SCC (n = 43) histologies separately with univariate log-rank test and multivariate Cox regression analyses.
    Results: In SCC cohort, mLNs > 2 was significantly associated with decreased 5-year disease-free survival (DFS) [hazard ratio (HR) = 2.06; 95% confidence interval (CI) 1.03-4.09; p = 0.03) and overall survival (OS) (HR = 2.35, 95% CI 1.11-4.99; p = 0.02). However mLNs > 2 had no significant impact on 5-year DFS and 5-year OS rates in non-SCC cohort (p = 0.94 and p = 0.94, respectively). We stratified the entire study population as SCC with mLNs ≤ 2, SCC with mLNs > 2, and non-SCC groups. Thereafter, we compared survival outcomes. The non-SCC group had worse 5-year OS (46.8% vs. 85.3%, respectively; p < 0.001) and 5-year DFS rates (31.6% vs. 82.2%, respectively; p < 0.001) when compared to those of the SCC group with mLNs ≤ 2. However, the non-SCC group and the SCC group with mLNs > 2 had similar 5-year OS (46.8% vs. 65.5%, respectively; p = 0.16) and 5-year DFS rates (31.6% vs. 57.5%, respectively; p = 0.06).
    Conclusion: Node-positive cervical cancer patients who have non-SCC histology as well as those who have SCC histology with mLNs > 2 seem to have worse survival outcomes when compared to women who have SCC histology with mLNs ≤ 2.
    MeSH term(s) Carcinoma, Squamous Cell/pathology ; Female ; Humans ; Lymph Node Excision ; Lymph Nodes/pathology ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Uterine Cervical Neoplasms/pathology
    Language English
    Publishing date 2021-03-27
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 896455-5
    ISSN 1432-0711 ; 0932-0067
    ISSN (online) 1432-0711
    ISSN 0932-0067
    DOI 10.1007/s00404-021-06030-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The prognostic significance of stage I ovarian clear cell and endometrioid carcinomas arising from endometriotic cysts: is it a myth?

    Ayhan, Ali / Akilli, Huseyin / Haberal, Nihan

    Archives of gynecology and obstetrics

    2018  Volume 299, Issue 1, Page(s) 217–222

    Abstract: Purpose: The aim of this study was to determine the clinicopathologic features and the prognostic significance of Stage I ovarian clear cell and endometrioid carcinomas arising from endometriotic cysts.: Materials and methods: Patients with either ... ...

    Abstract Purpose: The aim of this study was to determine the clinicopathologic features and the prognostic significance of Stage I ovarian clear cell and endometrioid carcinomas arising from endometriotic cysts.
    Materials and methods: Patients with either Stage I ovarian clear cell or endometrioid carcinoma were divided into three groups. *Group 1: Patients with cancers arising from endometriotic cysts *Group 2: Patients with ovarian and pelvic endometriosis *Group 3: Patients without endometriosis Patient characteristics (overall survival and disease-free survival) were compared between groups.
    Results: Of the 78 patients who participated in this study, 39 were in group 1, 13 were in group 2, and 26 were in group 3. The mean age in groups 1, 2, and 3 were 46 years, 54 years, and 48 years, respectively (p = 0.39). Tumoral characteristics, including capsule rupture, positive cytology, grade, and the presence of synchronous endometrial cancer were similar in both groups. The 5-year overall survival rate in groups 1, 2, and 3 were 100, 90, and 93%, respectively (p = 0.4). Moreover, the recurrence rates did not differ significantly between groups. Furthermore, subgroup analysis of clear cell carcinoma and endometrioid adenocarcinoma separately showed no effect of endometriosis on disease-free survival (DFS) or overall survival (OS).
    Conclusion: Clear cell or endometrioid ovarian carcinoma arising from ovarian and/or pelvic endometriosis shares the same clinicopathologic characteristics with their counterparts that do not arise from endometriosis and patients have similar overall and disease-free survival.
    MeSH term(s) Adenocarcinoma, Clear Cell/pathology ; Adult ; Carcinoma, Endometrioid/pathology ; Cysts ; Disease-Free Survival ; Endometrial Neoplasms/pathology ; Endometriosis/pathology ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Ovarian Neoplasms/pathology ; Prognosis ; Survival Rate
    Language English
    Publishing date 2018-10-12
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 896455-5
    ISSN 1432-0711 ; 0932-0067
    ISSN (online) 1432-0711
    ISSN 0932-0067
    DOI 10.1007/s00404-018-4935-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer.

    Günakan, Emre / Tohma, Yusuf Aytaç / Karakaş, Latife Atasoy / Akıllı, Hüseyin / Haberal, Asuman Nihan / Ayhan, Ali

    Obstetrics & gynecology science

    2020  Volume 63, Issue 4, Page(s) 464–469

    Abstract: Objective: Epithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and there are limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions of stage ... ...

    Abstract Objective: Epithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and there are limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions of stage 1a EOC patients. Prognostic effects of these gene expressions, as well as those of other factors on short term survival were analyzed.
    Methods: Our study included 29 patients. The specimens of the ovary with cancer were stained for p16 and p53. Gene expressions and other prognostic factors were evaluated.
    Results: The median age of the patients was 51 years (27-84). The mean numbers of dissected pelvic and paraaortic lymph nodes were 27 and 12, respectively. The mean follow-up time was 33.7±18.9 months. During this period, recurrence occurred in two patients. One of the patients had grade 2 mucinous carcinoma and died of the disease at month 12 after the recurrence occurred at month 7. The second patient had clear cell carcinoma and recurrence occurred at month 34. p16 and p53 gene expressions or other factors were not associated with overall survival (OS) or disease-free survival in the short term. The lower p16 positivity rate in the non-clear cell group was found to be statistically significant (P=0.003). Both p53 and p16 positivity rates were higher in the high-grade carcinoma.
    Conclusion: The levels of none of the common prognostic factors, including those of p16 and p53 gene expression, were associated with the progression-free survival or OS of stage 1a in the short term. Appropriate surgical staging and non-omission of subclinical metastases seem to be of central importance.
    Language English
    Publishing date 2020-06-19
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2814367-X
    ISSN 2287-8580 ; 2287-8572
    ISSN (online) 2287-8580
    ISSN 2287-8572
    DOI 10.5468/ogs.19204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Nulliparity and postmenopausal status are independent factors of malignancy potential of endometrial intraepithelial neoplasia in polyps.

    Karakas, Latife Atasoy / Atilgan, Alev Ok / Akilli, Huseyin / Kuscu, Ulku Esra / Haberal, Ali / Ayhan, Ali

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

    2020  Volume 152, Issue 3, Page(s) 433–438

    Abstract: Objective: To estimate the risk of concurrent endometrial cancer in endometrium when endometrial intraepithelial neoplasia (EIN) is found within an endometrial polyp and to identify the possible predictive factors for concurrent endometrial cancer.: ... ...

    Abstract Objective: To estimate the risk of concurrent endometrial cancer in endometrium when endometrial intraepithelial neoplasia (EIN) is found within an endometrial polyp and to identify the possible predictive factors for concurrent endometrial cancer.
    Methods: Histopathologic data of women who underwent hysteroscopy for resection of endometrial polyps at Ankara Baskent University Hospital, between 2011 and 2019 were screened. Patients whose polypectomy report was EIN in a polyp, and who had a final report of the hysterectomy specimen were included. Patients were divided into two groups according to the presence of concurrent cancer in the hysterectomy material: group 1, concurrent cancer present and group 2, concurrent cancer absent. Statistical analyses were performed using SPSS.
    Results: A total of 4125 women underwent hysteroscopy for the resection of endometrial polyps. Of those women, 161 (3.9%) were diagnosed as having EIN and 115 met the criteria. The rate of concurrent endometrial cancer was 28.6% (33/115). According to multivariate analysis, nulliparity (odds ratio [OR] 0.38; 95% confidence interval [CI] 1.04-3.67; p = 0.036) and postmenopausal status (OR 0.64; 95% CI 0.42-0.98; p = 0.042) were found to be independent factors significantly associated with concurrent endometrial cancer.
    Conclusion: The incidence of concurrent cancer is higher in postmenopausal or nulliparous women when EIN is detected in a polyp.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Endometrial Hyperplasia/epidemiology ; Endometrial Hyperplasia/pathology ; Endometrial Neoplasms/epidemiology ; Endometrial Neoplasms/pathology ; Female ; Humans ; Hysteroscopy ; Menopause ; Middle Aged ; Parity ; Polyps/epidemiology ; Polyps/pathology ; Pregnancy ; Retrospective Studies ; Risk Factors ; Turkey/epidemiology
    Language English
    Publishing date 2020-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80149-5
    ISSN 1879-3479 ; 0020-7292
    ISSN (online) 1879-3479
    ISSN 0020-7292
    DOI 10.1002/ijgo.13448
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Risk factors for sexual dysfunction in pregnant women during the COVID-19 pandemic.

    Karakas, Latife A / Azemi, Asli / Simsek, Seda Y / Akilli, Huseyin / Esin, Sertac

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

    2020  Volume 152, Issue 2, Page(s) 226–230

    Abstract: Objective: To evaluate the level of sexual function during the COVID-19 pandemic in pregnant women followed up in Baskent University Faculty of Medicine, Turkey, using the Female Sexual Function Index (FSFI).: Methods: An observational analysis was ... ...

    Abstract Objective: To evaluate the level of sexual function during the COVID-19 pandemic in pregnant women followed up in Baskent University Faculty of Medicine, Turkey, using the Female Sexual Function Index (FSFI).
    Methods: An observational analysis was performed on pregnant women who were not infected with COVID-19. A total of 135 pregnant women (group 1), 45 of whom were in the first trimester, 45 in the second trimester, and 45 in the third trimester, and 45 healthy women who were not pregnant (group 2), were included in the study. The FSFI was used to assess sexual dysfunction status.
    Results: A total of 118 (87.4%) pregnant participants and 31 (68.9%) non-pregnant participants were diagnosed as having sexual dysfunction according to the FSFI. When comparing groups 1 and 2, FSFI scores were significantly lower in group 1 (p = 0.002). It was also found that women who had university degrees, were multiparous, and in the third trimester were more likely to develop sexual dysfunction (p = 0.030, p = 0.029, and p = 0.001, respectively). FSFI scores were found to be significantly higher in planned pregnancies than in unplanned pregnancies (p = 0.001).
    Conclusion: The sexual function of uninfected pregnant women decreased during the COVID-19 pandemic, negatively influenced by restrictive social distancing measures.
    MeSH term(s) Adult ; COVID-19 ; Female ; Genital Diseases, Female/epidemiology ; Humans ; Pandemics ; Pregnancy ; Pregnancy Trimester, First ; Pregnancy Trimester, Second ; Pregnancy Trimester, Third ; Risk Factors ; Sexual Behavior ; Sexual Dysfunction, Physiological/epidemiology ; Surveys and Questionnaires ; Turkey ; Young Adult
    Keywords covid19
    Language English
    Publishing date 2020-12-23
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 80149-5
    ISSN 1879-3479 ; 0020-7292
    ISSN (online) 1879-3479
    ISSN 0020-7292
    DOI 10.1002/ijgo.13462
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top